In the EBVaGC cell line, the inhibition of JAK2, PI3K and mTOR by fedratinib, AZD1480 and LY294002, respectively, can inhibit the expression of PD-L1, thereby preventing cancer cells from evading surveillance of the immune system [89]. This evidence concerns the gene CD274 and cancer.